Equity Partner

23/F, R&F Center, 10 Huaxia Road
Zhujiang New Town, Tianhe District, Guangzhou

86 20 2826 1786/ 852 9856 8969

Highly regarded

English and Cantonese



Practice areas:


Wayne Wang is admitted in Mainland China, Hong Kong, and Australia.  He specializes in M&A, finance, and China outbound investment, with extensive experiences in energy/resources, pharmaceuticals/healthcare,  TMT and real estate.  He works for both foreign and PRC clients and is skilled at managing cross border M&A and financing deals involving multiple jurisdictions as the transaction counsel.   Prior to joining Zhong Lun, he had worked with a top tier Australian law firm in Shanghai and Hong Kong for 8.5 years and built up solid professional skills as an international commercial lawyer.   He also advises many Chinese companies doing M&A in Australia.  


Wayne Wang has acted as the lead partner and transaction counsel in the following cross border deals. 

  • Advised Beijing Konruns Pharmaceutical (PRC listed company code:603590) on their acquisition of certain osteoporosis drug (Terripetide and Miacalcic) assets of China NT Pharma Group (HKEX stock code: 01011) in consideration of approximately RMB 900 million.   This is one of the largest China outbound acquisition deals in the pharmaceuticals industry in the first half of 2020 and involves the laws of mainland China, Hong Kong, BVI, Cayman, Switzerland, USA, France and Germany.

  • Advised Guangzhou Metro (a large SOE of Guangdong, China) on its acquisition of shares in Yuexiu Property (HKEX Stock code 00123) in consideration of HKD 6.2 billion.  This is one of the largest cross-border acquisition deals in the Greater Bay Area in 2019.  After this deal, Guangzhou Metro became the 2nd largest shareholder of Yuexiu Property, which is a top tier real estate developer of China. 

  • Advised SATS LTD. (a listed company and the largest employer of Singapore) on its acquisition of 50% shares in Nanjing Weizhou Airline Food Co., Ltd. (a PRC company listed on the National Equities Exchange and Quotations (NEEQ)) in consideration of RMB 156.2 million.  After the acquisition, the target company was delisted from the NEEQ on 21 August 2019.

  • Advised Jollychic (an e-commerce unicorn of China) on its series C+ financing of USD 65 million.  This deal involved the laws of mainland China, Hong Kong and BVI and there were complicated issues such as cross border restructure and issuance of convertible notes in Hong Kong and BVI. 

  • Advised Guangdong Energy Group on a cross border LNG supply agreement with a large size foreign gas company, which involved a huge value.

  • M&A
  • Private equity
  • Banking
  • Covered bonds
  • Project finance

  • Banking
  • Energy
  • Pharma and life sciences
  • Real estate
  • Tech and telecoms 


  • PRC lawyer
  • Solicitor of Hong Kong
  • Solicitor of NSW, Australia


  • The Law Society of Hong Kong
  • The Law Society of NSW, Australia 
  • All China Lawyers Association

  • LLB, Sun Yat-sen University, China 
  • LLM, University of New South Wales, Australia 
  • Diploma in Law, Legal Profession Admission Board, NSW, Australia 
  • Graduate Diploma in Legal Practice, College of Law, NSW, Australia